1

RESEARCH PROCESS IN PHCA -

PHARMACOECONOMICSJinender Kumar

MS Candidate, 2nd Year (PHCA)

2

Pharmacoeconomics Research Uses of Pharmacoeconomics Research Need for Pharmacoeconomics Research Types of Pharmacoeconomics Research Sensitivity Analysis Discounting Journals References

Preview

3

PHARMACOECONOMICS RESEARCH Sub-discipline of health economics compares the costs (i.e resources consumed)

and consequences (i.e economic, clinical and humanistic) of the drug therapies and medical interventions

PE analysis efficient allocation of limited resources among

competing alternative medications and services biggest bang for your buck

4

VALUE

Health Outcome

Cost

5

USE OF PHARMACOECONOMIC RESEARCH Pharmaceutical reimbursement Selecting formulary products Price Negotiations Clinical Practice Development guidelines Communication to prescribing physicians

6

NEEDS TO MONITOR VALUE OF PHARMACEUTICALS Increased cost. Increased number of alternatives available to

treat illness and disease. Growing demand for pharmaceuticals. Introduction of high cost biotechnology

products.

7

TYPES OF PHARMACOECONOMIC EVALUATION Cost-minimization analysis (CMA) Cost-benefit analysis (CBA) Cost-effectiveness analysis (CEA) Cost-utility analysis (CUA) Cost-consequence analysis (CCA)

8

COMPARING PHARMACOECONOMIC METHODOLOGIES

METHODOLOGY

Cost-Minimization

Cost-Effectiveness

Cost-Benefit

Cost-Utility

Cost-Consequence

CONSEQUENCES

Natural Units

Natural Units

Dollars

Quality-Adjusted Life Years (QALYs)

Natural Units, Dollars or

QALYs

9

STEPS FOR CONDUCTING A PHARMACOECONOMIC EVALUATION Defining the problem and stating the

objective. Identifying the perspective and alternative

interventions to be compared. Identifying and measuring the outcomes of

each alternative. Identifying, measuring and valuing the costs

of all alternatives.

10

DEFINE THE PROBLEM AND STATE THE OBJECTIVE All pharmacoeconomic evaluation should

have a clear and concise statements of problem or question to be addressed.

E.g. What is the most cost-effective regimen for the

treatment of type II diabetes? To estimate the cost effectiveness of olanzapine

and risperidone for the treatment of schizophrenia Cost-Minimization Analysis of Once-Weekly Versus

Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia

11

PERSPECTIVE

Point of view from which the study is taken Determines what will be measured, what are

the costs and benefits, and how they will be valued

Guides and limits application of study results What are the possible perspectives in PE

studies?

12

PERSPECTIVE

Pharmacoeconomic evaluation can be conducted from several different perspectives including the employer, the patient, the health insurance plan, society, or the government.

13

IDENTIFYING ALTERNATIVE INTERVENTIONS Which alternative should be compared in

pharmacoeconomic evaluation?

14

IDENTIFYING ALTERNATIVE INTERVENTIONS Alternatives should be compared only when

one of the alternatives is either more costly or more effective.

15

IDENTIFY AND MEASURE OUTCOMES OF EACH ALTERNATIVE INTERVENTIONSome of the outcomes of the treatment are: A cure (health is restored) Improved quality of life Decreased incidence of morbidity Extended life Relief or reduction in symptoms No effect Increased morbidity Mortality

16

OUTCOMES

Both positive and negative outcomes should be addressed

Positive outcomes: drug’s efficacy measure Negative outcomes: ADR and treatment

failure

17

IDENTIFYING,MEASUREMENT AND VALUATION OF COSTS

From the measurement aspect, two components are costs and consequences

Three important concepts related to costs are identifying, measuring, and placing a value on resources or costs.

18

IDENTIFYING RELEVANT COSTS What is cost?

How is cost different from price?

19

COSTS

Direct costs: costs to deliver services to patient; both medical and non-medical

Indirect costs: cost of treatment to patient or society

Intangible costs: quality of life

20

Costs can be described in many ways Cost / unit (cost/tab, cost/vial) Cost / treatment Cost / person Cost / person / year Cost / case prevented Cost / life saved Cost / DALY (disability-adjusted life year)

21

MEASURING COSTS

After cost identification the next step involves measuring the costs.

Measurement involves counts of resources consumed in units depending on the type of costs.

22

VALUING COSTS

After cost measurement, the next step involves placing a dollar value on the resources.

23

SENSITIVITY ANALYSIS

Test key outcome or cost assumption of an analysis to determine how sensitive the results are to variation or to uncertainty.

In pharmacoeconomic evaluations, the accuracy with which costs can be identified, measured, or valued will vary.

24

DISCOUNTING

The purpose of discounting is to present all costs in their present value and to incorporate the society’s time preference for money.

Alternatives that have costs or benefits realized at different times should be discounted to a present value to make valid comparisons.

25

COST-MINIMIZATION ANALYSIS (CMA) CMA compares the cost and consequences of two

or more therapeutic interventions that are equivalent in their outcomes or consequences.

E.g. Comparison between brand and generic drugs Comparison of different routes of administration of the

same drug Comparison of different setting for the administration of the

same drug therapy. Comparison of different dosages of the same drug at

different time points (OW vs. TIW)

26

COST-MINIMIZATION ANALYSIS (CMA) The cost differences can be presented as

average cost per patient or average cost of care if number of patients are same under each alternative

27

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia

This study was published in JMCP in 2004. The investigators main objective was to

conduct a cost-minimization analysis comparing OW and TIW EPO dosing from a societal perspective.

Various Clinical studies have established the clinical equivalency between OW (40000 units) and TIW (10000 units) EPO dosing.

28

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia

OW dosing requires additional 10000 units per week The investigators compared the direct and indirect

cost associated with OW and TIW EPO dosing by using the data from 2 large community based trials.

Resource utilization data was available in both studies for- EPO, transfusion, laboratory tests, office visits, and opportunity cost of patient time resources over the period during which the patient remained in the study.

Costs were calculated by applying cost estimates of specific procedures from the published literature.

29

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia

Cost assumptions are provided in Table 5 All cost are measure in 2002 US Dollars Total costs, sensitivity analysis and the break points

for statistically significant differences are shown in Table 6

For OW dosing, transfusion, laboratory cost and time costs were lower than TIW dosing

The investigators did not consider the cost associated with the caregiver time and intangible cost of avoiding two painful injections each week.

30

COST-EFFECTIVENESS ANALYSIS (CEA) Most frequently used method CEA is restricted to situations in which the

outcomes of the alternative are measured on the same scale, such as mm Hg or serum cholesterol level.

CEA determines which alternative can achieve the best outcome at the lowest cost.

31

COST-EFFECTIVENESS ANALYSIS (CEA) The results of CEA are presented as the

incremental ratio of costs to outcomes

Alternative Average cost per patient

Outcome (Success rate)

Average cost effectiveness ratio

ICER

A $85 0.55 $155/SUCCESFUL CASE

B $150 0.80 $187/SUCCESFUL CASE

$260/ADDITIONAL SUCCESSFUL CASE TREATED

C $95 0.78 $122/SUCCESFUL CASE

$43/ADDITIONAL SUCCESSFUL CASE TREATED

32

COST-BENEFIT ANALYSIS (CBA) CBA measures outcomes in dollars value CBA include studies which are conducted to

make decisions with a broad societal impact E.g.

Whether to fund immunization programs or implement child safety seat legislation (will help government decide which program to implement with limited budget)

33

COST-BENEFIT ANALYSIS (CBA) Two most commonly used methods to

determine cost benefits are Net benefit and Cost-to-benefit or benefit-to-cost ratio.

Net Benefit=Benefits-cost (for programs less than a year)

Benefit-to cost-ratio=Benefits/costs

34

COST-UTILITY ANALYSIS (CUA) CUA measures outcomes as lives saved CUA measure both the quantity and quality

aspects of gain in life years (adjusts the gain in life years for quality – measured as QALYs)

In CUA, life years are converted to QALY by applying a utility value (0-1) 0-death, 1-perfect health Most health states fall between these extremes

35

COST-UTILITY ANALYSIS (CUA) CUA is often considered an extension of CEA CEA measures Incremental cost

effectiveness ratio (ICER) CUA measures Incremental cost utility ratio

(ICUR) ICER=Additional cost of therapy/additional

life years ICUR= Additional cost of therapy/additional

QALY

36

COST-CONSEQUENCE ANALYSIS (CCA) CCA presents all costs and effects in a

disaggregated formatCost (per Patient) Drug A Drug B

Direct Medical Units Costs Units Costs

Drug therapy - - - -

Physician costs - - - -

Hospitalizations - - - -

Direct Non Medical - - - -

Transportation - - - -

Caregiver time - - - -

Indirect - - - -

Productivity (lost days/episode) - - - -

Consequences - - - -

Clinical - - - -

Cases successfully treated - - - -

Quality of life (QALY) - -- - -

37

COST-CONSEQUENCE ANALYSIS (CCA) Decision makers can chose among the costs

and outcomes that best fit their perspective The advantages of CCA are its

comprehensiveness and transparency for the decision makers

The disadvantages for the researchers are that they must identify, collect, and value cost and outcomes salient to a variety of perspectives.

38

JOURNALS

Value in Health Pharmacoeconomics Health Economics Pharmacoeconomics and Outcomes News Clinical Therapeutics - Pharmaceutical

Economics & Health Policy Health Affairs (The Policy journal)

39

REFERENCES

1. http://ispor.org/Terminology/Default.asp

2. Bootman JL, Townsend RJ, Mcghan WF. Principles of Pharmacoeconomics. 3 rd edition. Harvey Books Company. 2005.

3. McCArthy Rl, Schafermeyer KW. Introduction to Health Care Delivery. 3rd edition. Jones and Barlett Publisher. 2004.

4. Bonk RJ. Pharmacoeconomics in Perspective:a primer on reseach, techniques and perspective. Pharmaceutical product press. 1999.

5. Rychlik R.Strategies and Pharmacoeconomics and Outcomes Research. Pharmaceutical Heritage Edition. 2003.

6. Vogenberg FR. Introduction to Applied Pharmacoeconomics. Mcgraw-Hill Publications. 2001.